Kanada - engelska - Health Canada

glenmark pharmaceuticals canada inc. - ursodiol - tablet - 500mg - ursodiol 500mg - cholelitholytic agents

Kanada - engelska - Health Canada

pendopharm division of pharmascience inc - ursodiol - tablet - 250mg - ursodiol 250mg - cholelitholytic agents

Kanada - engelska - Health Canada

pendopharm division of pharmascience inc - ursodiol - tablet - 500mg - ursodiol 500mg - cholelitholytic agents

USA - engelska - NLM (National Library of Medicine)

carilion materials management - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - 1. ursodiol is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest  diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. safety of use of ursodiol beyond 24 months is not established. 2. ursodiol is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. - ursodiol will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. hence, patients with such stones are not candidates for ursodiol therapy. - patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for ursodiol therapy. - allergy to bile acids.

Kanada - engelska - Health Canada

sanis health inc - ursodiol - tablet - 250mg - ursodiol 250mg - cholelitholytic agents

Kanada - engelska - Health Canada

sanis health inc - ursodiol - tablet - 500mg - ursodiol 500mg - cholelitholytic agents

USA - engelska - NLM (National Library of Medicine)

avkare - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol tablets, usp are indicated for the treatment of patients with primary biliary cirrhosis (pbc). patients with complete biliary obstruction and known hypersensitivity or intolerance to ursodiol or any of the components of the formulation. pregnancy category b. reproduction studies have been performed in pregnant rats at oral doses up to 22 times the recommended maximum human dose (based on body surface area) and in pregnant rabbits at oral doses up to 7 times the recommended maximum human dose (based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to ursodiol. there are no adequate or well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. it is not known whether ursodiol is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when ursodiol are administered to a nursing mother. the safety and effectiveness of ursodiol in pediatric patients have not been established.

Kanada - engelska - Health Canada

angita pharma inc. - ursodiol - tablet - 250mg - ursodiol 250mg - cholelitholytic agents

Kanada - engelska - Health Canada

angita pharma inc. - ursodiol - tablet - 500mg - ursodiol 500mg - cholelitholytic agents

Kanada - engelska - Health Canada

mint pharmaceuticals inc - ursodiol - tablet - 250mg - ursodiol 250mg - cholelitholytic agents